EKF Diagnostics Investor Announcements

EKF Diagnostics Holdings plc is an in-vitro diagnostics (IVD) business. The Company is engaged in the designing, development, manufacture and selling of diagnostic analyzers, reagents and ancillary products. This activity takes place across several geographical locations which include the United Kingdom, United States of America, Germany, Poland and Russia.

Pages:

22

Second Price Monitoring Extension

17^th Mar 2016

Price Monitoring Extension

17^th Mar 2016

Notice of Results

17^th Mar 2016

EKF Diagnostics Holdings plc announces Notice of Results.

3^rd Feb 2016

EKF Diagnostics Holdings plc announces a trading update for the year ended 31 December 2015.

TR-1 notification of major interest in shares

20^th Jan 2016

TR-1 notification of major interest in shares

18^th Jan 2016

Price Monitoring Extension

18^th Jan 2016

TR-1 notification of major interest in shares

15^th Jan 2016

23^rd Dec 2015

EKF Diagnostics Holdings plc announces that it has reached agreement to sell its wholly owned subsidiary Selah Genomics, Inc.

22^nd Dec 2015

EKF Diagnostics Holdings announces that it has reached agreement to borrow £3 million by way of convertible loan from Zwanziger Family Ventures LLC.

Pages:

22

Archive

2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011

Mount Sinai investments related

RNS announcements

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF Diagnostics is previewing the new connectivity solution for A1c POC analyzers at Medica 2016

EKF Diagnostics is previewing a new point-of-care (POC) connectivity solution for its range of HbA1c analyzers at Medica 2016 in Düsseldorf from 14–17^th November.

Glycated Serum Protein LiquiColor test verified for Siemens Vista chemistry analyzer

EKF Diagnostics, the global in vitro diagnostics company, announces that its newly introduced Glycated Serum Protein (GSP) LiquiColor^® diabetic biomarker test has been verified for use on the Siemens Vista chemistry analyzer

Separation Technology moves its production and operations facility to Boerne, Texas

EKF Diagnostics, the global in-vitro diagnostics company, announces that Separation Technology, Inc., a subsidiary of EKF, has moved its manufacturing and operations from Sanford, Florida to Boerne, Texas.

EKF Diagnostics' Quo-Test HbA1c analyzer achieves class leading level of performance

EKF Diagnostics, the global in-vitro diagnostics company, announces the release of a significant critical evaluation of the Quo-Test analyzer carried out by the European Reference Laboratory for Gylcohemoglobin.

EKF Diagnostics has Point-of-Care at its heart

EKF Diagnostics, the global in vitro diagnostics company, is looking forward to an exciting second half of 2016 as it relaunches the HemoPoint® H2 hemoglobin analyzer in the USA under the Stanbio brand.

Product showcase

Copyright © 2024 | Powered by Intergage

Quick links

News and Events

Anemia and Hemoglobin testing

Diabetes and HbA1c testing

Support

Social media

EKF Diagnostics - web 50px

Please note: Not all products are available in all countries. Please check availability.

Privacy | Terms & Conditions | Terms of Sale | ESG Statement | UK Modern Slavery Act